Metonitazene: Complete Toxicology, Overdose, Dependence, Withdrawal & Safety Monograph

Metonitazene: Complete Toxicology, Overdose, Dependence, Withdrawal & Safety Monograph

Emergency opioid warning: Metonitazene is a potent synthetic opioid. If someone cannot be awakened, has slow/irregular/stopped breathing, blue or gray lips/skin, gurgling/choking, or collapses after an unknown pill, powder, vape, or opioid-like product, call emergency services and give naloxone if available. Do not wait for the exact drug to be identified.

Quick answer

Metonitazene is a potent nitazene-class synthetic opioid with established human fatality evidence, a history of appearing in counterfeit medicines, and no approved medical use.

It belongs to the 2-benzylbenzimidazole opioid family first investigated in mid-20th-century medicinal chemistry. The modern illicit-market signal emerged around 2020.

The human evidence is stronger than a short “research chemical” profile suggests:

• a U.S. forensic series documented 20 postmortem cases;
• a 2026 Swedish study analyzed 57 nitazene-positive autopsies, with metonitazene the most common analogue (38 cases);
• a 2026 Norwegian national series found 28 metonitazene-positive deaths among 36 nitazene-related deaths from 2021–2024;
• WHO documented falsified Oxymorphone 40 mg tablets that actually contained metonitazene;
• metabolism research now identifies useful blood and urine biomarkers.

Most fatal cases are polysubstance cases, which means detection must not be simplified into sole causation. But metonitazene-only/mono-intoxication findings and repeated international casework establish that intrinsic opioid toxicity is real.

Identity

Metonitazene must not be confused with N-pyrrolidino metonitazene (metonitazepyne). They are related nitazenes but chemically distinct compounds with separate evidence and scheduling histories.

History

The nitazene scaffold comes from analgesic research conducted decades before the current overdose crisis. Compounds in this family were not adopted as routine medicines.

Modern metonitazene appeared in forensic drug markets in 2020. DEA's federal record notes the first U.S. seizure in July 2020 in North Carolina.

Its trajectory mirrors other NPS opioids:

1. old medicinal-chemistry scaffold;
2. reappearance in unregulated markets;
3. forensic toxicology detections and deaths;
4. scheduling;
5. substitution by newer analogues.

WHO reviewed metonitazene in 2021 because of its opioid mechanism, dependence/abuse potential, fatalities, and lack of recognized therapeutic use. International control followed in 2022.

Pharmacology

Metonitazene is a mu-opioid receptor agonist.

In-vitro nitazene studies show that members of this family can equal or exceed fentanyl in specific receptor assays. A 2026 Swedish forensic/pharmacology study found the tested nitazenes had MOR potencies in the sub-nanomolar to low-nanomolar range and efficacies comparable to or exceeding fentanyl.

Why “X times fentanyl” is not a human dose conversion

Potency depends on:

• assay;
• endpoint;
• receptor system;
• species;
• administration route;
• metabolism.

A receptor EC50 ratio is not a validated human respiratory-depression ratio and should never be turned into a consumer dose calculation.

The evidence-based conclusion is simpler: metonitazene is a high-potency MOR agonist capable of fatal opioid toxicity at low measured biological concentrations.

Human fatality evidence

U.S. postmortem series

A 2021 U.S. forensic study documented metonitazene in 20 postmortem cases.

Fentanyl was present in more than half, illustrating the polysubstance nature of the illicit opioid supply. Metonitazene was the only opioid identified in a meaningful subset, supporting the conclusion that it can produce severe/fatal opioid toxicity without fentanyl being present.

Sweden: 57 nitazene-positive autopsies

A 2026 Swedish study analyzed 57 nitazene-positive autopsy cases received from 2020–2024.

Metonitazene was the most encountered nitazene, present in 38 cases.

In metonitazene mono-intoxication cases, femoral blood concentrations ranged from 0.3 to 34 ng/g.

That range is useful for forensic context, not a lethal-dose chart. Blood concentration depends on tolerance, timing, co-drugs, specimen, postmortem processes and individual factors.

Norway: national fatality series

A 2026 Norwegian study found 36 nitazene-related deaths from 2021–2024, with metonitazene detected in 28.

More than 90% of the overall nitazene cases also involved at least one other psychoactive drug, and half involved one or more designer benzodiazepines.

That is a crucial real-world lesson: nitazene mortality often occurs inside a polysubstance supply.

Japan

A published Japanese postmortem case provides additional direct fatal-intoxication evidence outside North America and Europe.

Counterfeit medicines and unintentional exposure

Metonitazene can reach people who did not intend to use a nitazene.

In 2024, WHO issued a medical-product alert after laboratory testing of a falsified product labeled Oxymorphone Hydrochloride 40 mg found metonitazene instead.

This is more than a branding problem.

A person expecting one opioid may make decisions based on:

• a familiar tablet appearance;
• an expected onset/duration;
• perceived tolerance;
• prior experience with the labeled drug.

When the actual drug is a different high-potency synthetic opioid, those assumptions become unreliable.

Acute toxicity and overdose

Metonitazene toxicity follows an opioid pattern:

• profound sedation;
• pinpoint pupils;
• slowed or irregular breathing;
• hypoxia;
• unresponsiveness;
• bradycardia/hypotension in severe cases;
• aspiration;
• cardiac arrest;
• death.

Co-use with fentanyl, benzodiazepines, alcohol, gabapentinoids, xylazine or other sedatives can complicate the presentation and increase danger.

Naloxone

Naloxone is appropriate for suspected metonitazene/nitazene opioid overdose.

Human nitazene clinical evidence shows that naloxone can reverse opioid toxicity. Repeat treatment and continued observation can be necessary because:

• the analogue may be unknown;
• dose/concentration may be unknown;
• re-sedation can occur;
• multiple opioids or sedatives may be present.

There is no evidence-based consumer “metonitazene naloxone formula.” Emergency care remains necessary.

Metabolism

A 2024 human-metabolism study examined metonitazene using pooled human hepatocytes and authentic postmortem specimens.

Researchers identified nine metabolites.

Major pathways included:

• N-deethylation;
• O-dealkylation;
• further O-glucuronidation.

Suggested exposure biomarkers include:

• parent metonitazene;
• O-dealkyl metabolite;
• N-deethyl-O-dealkyl metabolite in urine after glucuronide hydrolysis;
• N-desethyl metabolite as an additional blood biomarker.

The 2026 Swedish study also found possible N-desethyl, acetamido and 5-amino metonitazene signals while cautioning that some products may reflect metabolism, degradation or storage effects.

That distinction matters in postmortem interpretation.

Pharmacokinetics: what is still missing

Controlled human pharmacokinetic studies have not established a clinically reliable:

• oral bioavailability;
• time to peak concentration;
• half-life;
• dose-concentration curve;
• repeated-use accumulation model;
• renal/hepatic adjustment.

Forensic metabolism is not the same thing as a controlled human PK trial.

Testing and detection

Routine screening

Routine emergency or workplace immunoassays are not designed to reliably detect the expanding nitazene family.

A negative “opioid” or fentanyl test therefore does not rule out metonitazene.

Definitive testing

Confirmation generally requires:

• LC-MS/MS;
• LC-HRMS / QTOF;
• validated targeted or broad-spectrum methods;
• appropriate standards;
• inclusion of relevant metabolites.

Because active concentrations can be low, analytical sensitivity matters.

Why metabolites matter

Parent drug may be low, degraded or no longer detectable in some specimens.

Validated metabolites can:

• strengthen proof of exposure;
• extend detection windows;
• help distinguish true exposure from analytical noise.

They do not automatically prove impairment or causation.

Forensic interpretation

A metonitazene concentration in a death is not a personal toxicity calculator.

Interpretation requires:

• specimen type;
• postmortem redistribution/degradation;
• tolerance;
• co-drugs;
• route and timing;
• metabolites;
• disease/injury;
• scene evidence.

The same concentration can carry different meaning in different cases.

Detection vs contribution vs sole causation

These are different claims:

1. Detected — the compound was analytically found.
2. Contributed — evidence supports a role in the toxic event.
3. Sole cause — no other major toxicological or medical factor explains the death.

Polysubstance series should not be rewritten as “metonitazene alone caused every death.”

Interactions and polysubstance risk

Highest concern involves other respiratory/CNS depressants:

• fentanyl and other opioids;
• benzodiazepines;
• alcohol;
• gabapentinoids;
• sedative-hypnotics;
• xylazine-containing mixtures.

Stimulants can add cardiac stress without protecting against opioid respiratory depression.

Tolerance and physical dependence

Repeated MOR agonism can produce tolerance and physical dependence.

Metonitazene-specific prospective dependence cohorts are not available, but the nitazene class has direct human evidence of withdrawal and opioid dependence.

It is scientifically reasonable to treat repeated metonitazene exposure as capable of producing opioid dependence while being honest that the incidence and exact time course are unknown.

Withdrawal

Expected opioid-type symptoms include:

• restlessness;
• sweating/chills;
• insomnia;
• runny nose/tearing;
• nausea, vomiting or diarrhea;
• abdominal cramps;
• muscle aches;
• anxiety;
• rapid pulse;
• craving.

No validated metonitazene-specific onset/peak/duration schedule exists.

A product may also change between batches or contain multiple opioids, making a brand-based home detox schedule unreliable.

Physical dependence vs opioid use disorder

Physical dependence means withdrawal occurs after adaptation.

Opioid use disorder is broader and can involve:

• craving;
• inability to cut down;
• escalating use;
• repeated hazardous use;
• continued use despite overdose or health harm;
• interference with work, family or responsibilities;
• time spent obtaining/using/recovering.

A person exposed through counterfeit medication can become dependent without knowingly choosing metonitazene.

Treatment and support

There is no metonitazene-specific approved withdrawal medication.

Clinicians can evaluate opioid withdrawal/OUD using established evidence-based opioid treatment frameworks.

Medications for opioid use disorder include:

• buprenorphine;
• methadone;
• extended-release naltrexone in appropriately selected patients after sufficient opioid abstinence.

This page intentionally does not provide self-induction or taper dosing.

U.S. resources:

• FindTreatment.gov
• SAMHSA National Helpline: 1-800-662-HELP (4357)

Emergency overdose, severe dehydration, pregnancy with significant withdrawal, severe confusion, chest pain, or suicidal thoughts require urgent medical evaluation.

Legal and regulatory history

United States

DEA temporarily placed metonitazene in Schedule I effective April 12, 2022.

A final federal order kept metonitazene in Schedule I effective September 18, 2023, in part to meet U.S. treaty obligations after international scheduling.

International

Metonitazene entered Schedule I of the 1961 Single Convention on Narcotic Drugs in 2022.

Legal status should still be checked by jurisdiction and date.

Special populations

Controlled metonitazene data are inadequate for:

• pregnancy/breastfeeding;
• adolescents;
• older adults;
• respiratory disease or sleep apnea;
• significant liver/kidney disease;
• seizure disorders.

For a potent opioid with incomplete human PK, missing data are not evidence of safety.

Myths and common misconceptions

“Metonitazene is exactly X times stronger than fentanyl.”
No universal human ratio exists. Potency estimates are assay-dependent.

“If fentanyl is negative, there is no opioid.”
False. Metonitazene can be present without fentanyl.

“A real-looking prescription pill means the ingredient is predictable.”
False. WHO documented falsified oxymorphone containing metonitazene.

“A fatal blood concentration tells me a lethal dose.”
False. Concentration, ingested dose, tolerance, timing and postmortem change are different variables.

“No metonitazene-specific withdrawal trial means it cannot cause dependence.”
False. Its MOR pharmacology and class evidence support real dependence risk; the unknowns are frequency and timeline.

Evidence ledger

Related evidence

• Nitazene opioids
• Isotonitazene
• Protonitazene
• N-Pyrrolidino Protonitazene
• N-Desethyl Protonitazene
• Designer synthetic opioids beyond nitazenes
• Substance Use, Dependence & Harm Reduction hub

Bottom line

Metonitazene is not a speculative opioid threat.

It has repeatedly appeared in fatal human casework across multiple countries, can replace the expected ingredient in falsified medicines, and occurs at concentrations that demand sensitive modern toxicology.

The most useful safety message is not a potency number.

It is that unknown opioid products can contain high-potency nitazenes that routine screening may miss, naloxone remains relevant, polysubstance exposure is common, and dependence should be treated with established opioid-care pathways rather than internet conversion charts.